Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Filip Hoet (Leuven, Belgium), Filip Hoet, Jonas Yzerbyt, Wim A. Wuyts. Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience. Eur Respir J 2016; 48: Suppl. 60, 787

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Interstitial lung abnormalities with a diagnosis of idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021 Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Predictors of esophageal dilatation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013